Show simple item record

dc.contributor.authorGracia-Marco, L
dc.contributor.authorGarcía-Fontana, B
dc.contributor.authorUbago-Guisado, E
dc.contributor.authorVlachopoulos, D
dc.contributor.authorGarcía-Martín, A
dc.contributor.authorMuñoz-Torres, M
dc.date.accessioned2019-10-09T08:31:03Z
dc.date.issued2019-10-07
dc.description.abstractContext primary hyperparathyroidism (PHPT) has been related to bone loss. Dual-energy X-ray absorptiometry (DXA) cannot distinguish between trabecular and cortical bone compartments but the recently developed 3D-DXA software might overcome this issue. Objective to examine the differences in DXA-derived areal bone mineral density (aBMD) and 3D-DXA parameters at the hip site between patients with PHPT and a healthy control group. Design cross-sectional pilot study Setting hospital Patients 80 adults (59.5 ± 9.1 yrs), 40 with PHPT and 40 healthy age- and sex-matched healthy controls. Measures aBMD (g/cm2) of the femoral neck, trochanter, shaft and total hip was assessed using DXA. Cortical surface (sBMD, mg/cm2), cortical volumetric BMD (vBMD, mg/cm3), trabecular vBMD (mg/cm3), integral vBMD (mg/cm3) and cortical thickness (mm) was assessed using 3D-DXA software. Results mean-adjusted values showed lower aBMD (7.5% to 12.2%, effect size: 0.51-1.01) in the PHPT group compared to the control group (all p<0.05). 3D-DXA revealed bone impairment (3.7% to 8.5%, effect size: 0.47-0.65) in patients with PHPT, mainly in cortical parameters (all p<0.05). However, differences in trabecular vBMD were not statistically significant (p=0.055). The 3D mapping showed lower cortical sBMD, cortical vBMD and cortical thickness at the trochanter and diaphysis in the PHPT group (p<0.05) compared to the control group. In both groups, the presence of osteopenia or osteoporosis is related to lower cortical bone. Conclusions aBMD and cortical 3D parameters are impaired in patients with PHPT versus healthy controls. The vBMD of the trabecular compartment seems to be affected though to a lower extent.en_GB
dc.description.sponsorshipFondo de Investigación Sanitariaen_GB
dc.description.sponsorshipFEDERen_GB
dc.description.sponsorshipLa Caixaen_GB
dc.identifier.citationPublished online 07-October-2019en_GB
dc.identifier.doi10.1210/clinem/dgz060
dc.identifier.grantnumberPI18/01235)en_GB
dc.identifier.grantnumberID 100010434en_GB
dc.identifier.urihttp://hdl.handle.net/10871/39121
dc.language.isoenen_GB
dc.publisherOxford University Press/Endocrine Societyen_GB
dc.rights.embargoreasonUnder embargo until 07 October 2020 in compliance with publisher policyen_GB
dc.rights© Endocrine Society 2019. All rights reserved.en_GB
dc.subjectparathyroid-related disordersen_GB
dc.subjectDXAen_GB
dc.subjectBone QCTen_GB
dc.subjectOsteoporosisen_GB
dc.subject3D-DXAen_GB
dc.titleAnalysis of bone impairment by 3D DXA hip measures in patients with primary hyperparathyroidism: a pilot studyen_GB
dc.typeArticleen_GB
dc.date.available2019-10-09T08:31:03Z
dc.identifier.issn0021-972X
dc.descriptionThis is the author accepted manuscript. The final version is available from The OUP via the DOI in this record en_GB
dc.identifier.journalThe Journal of Clinical Endocrinology & Metabolismen_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dcterms.dateAccepted2019-10-07
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2019-10-07
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-10-09T08:03:07Z
refterms.versionFCDAM
refterms.panelCen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record